Obesity is widely recognised as a global crisis, but one health expert has warned of a more insidious trend that’s wreaking havoc on our health and shortening lifespans. Speaking to Steven Bartlett, host of the Diary of CEO podcast, Dr Gabrielle Lyon emphasised the importance of exercise and strength training alongside diet. During their discussion, … Read more
Today marks World Alzheimer’s Day, a significant date dedicated to raising awareness and offering support for individuals and families coping with the disease. Alzheimer’s is a prevalent type of dementia and the leading cause of death in the UK. The term ‘dementia’ encompasses various symptoms like memory deterioration, confusion, and problems with speech and understanding. … Read more
Startling research suggests that people with untreated high blood pressure have a significantly worsened risk of dementia. Australian researchers examined data from more than 30,000 individuals across 14 different countries to better understand the relationship between cognitive health and hypertension. Disturbingly, their Neurology study found that ignoring blood pressure problems elevates personal risk of non-Alzheimer’s … Read more
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, … Read more
In a remarkable scientific stride, new research suggests that individuals with multiple sclerosis (MS) may possess a genetic edge that helps shield them from Alzheimer’s, igniting fresh hope for experts in their quest to discover a cure or preventive strategies. The study conducted by the Washington University School of Medicine in St. Louis indicates that … Read more
LONDON — Britain’s drug regulator authorized the Alzheimer’s drug Leqembi on Thursday, saying it’s the first medicine to show some impact in slowing the progression of the neurodegenerative disease. But the U.K. government likely won’t be paying for it after an independent agency separately issued draft guidance concluding that the benefits of Leqembi “cannot be … Read more
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over … Read more
WASHINGTON — New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported Sunday – but some appear to work far better than others. It’s tricky to tell if memory problems are caused by Alzheimer’s. That requires confirming one of the disease’s hallmark signs — buildup of a sticky protein called … Read more
WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second … Read more
This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here. Traders work on the floor of the New York Stock Exchange during morning trading on Oct. 4, … Read more
